Prelude Therapeutics (PRLD) Cash & Equivalents (2019 - 2026)
Prelude Therapeutics (PRLD) posted Cash & Equivalents of $84.8 million for Q1 2026, up 140.53% sequentially from $35.3 million in Q4 2025, and up 91.37% YoY from $44.3 million in Q1 2025.
Prelude Therapeutics (PRLD) Cash & Equivalents (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Cash & Equivalents for 8 years, with the latest figure at $84.8 million in Q1 2026.
- Quarterly Cash & Equivalents rose 91.37% year-over-year to $84.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.8 million (up 91.37% YoY) and the FY2025 annual result came in at $35.3 million, up 113.44% from the prior year.
- Cash & Equivalents advanced to $84.8 million in Q1 2026 per PRLD's latest filing, from $35.3 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $84.8 million in Q1 2026 and troughed at $15.2 million in Q3 2024.
- A 5-year average of $40.3 million and a median of $34.6 million in 2022 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 84.66% in 2022, then surged 213.16% in 2025.
- Over 5 years, Cash & Equivalents stood at $34.6 million in 2022, then slipped by 15.34% to $29.3 million in 2023, then plunged by 43.69% to $16.5 million in 2024, then jumped by 113.44% to $35.3 million in 2025, then jumped by 140.53% to $84.8 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $84.8 million, $35.3 million, and $47.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 155.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 155.20 Mn |
| Mar 31, 2026 | 84.80 Mn |
| Dec 31, 2025 | 35.26 Mn |
| Sep 30, 2025 | 47.53 Mn |
| Jun 30, 2025 | 77.30 Mn |
| Mar 31, 2025 | 44.31 Mn |
| Dec 31, 2024 | 16.52 Mn |
| Sep 30, 2024 | 15.18 Mn |
| Jun 30, 2024 | 31.87 Mn |
| Mar 31, 2024 | 28.75 Mn |
| Dec 31, 2023 | 29.34 Mn |
| Sep 30, 2023 | 19.94 Mn |
| Jun 30, 2023 | 30.49 Mn |
| Mar 31, 2023 | 22.25 Mn |
| Dec 31, 2022 | 34.65 Mn |
| Sep 30, 2022 | 56.07 Mn |
| Jun 30, 2022 | 54.75 Mn |
| Mar 31, 2022 | 55.68 Mn |
| Dec 31, 2021 | 35.87 Mn |
| Sep 30, 2021 | 61.42 Mn |